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the cost of treatment with Peg-Interferon Alpha-2a is lower compared to Peg-In-
terferon Alpha 2b. For a 10-year projection which simulates through a Markov
model that patients that did not respond to treatment evolved to chronicity of the
disease costs per patient with Peg-interferon Alpha-2a was $ 25,913, while with
Peg-Interferon Alpha-2b was $ 37,352, generating savings of $ 11,439 per patient
who was treated with Peg-interferon Alpha-2a. CONCLUSIONS: The use of Peg-
Interferon Alpha-2a was the dominant alternative because it was the most effec-
tive and least costly to treat HCV.
PGI12
THE IMPACT OF TNF INHIBITORS FOR CROHN’S DISEASE ON HEALTH CARE
RESOURCE UTILIZATION: AN ANALYSIS USING THE RAMQ DATABASE
Lachaine J1, Feagan B2, Martel MJ3, Beauchemin C1, Mchugh K4
1University of Montreal, Montreal, QC, Canada, 2Robarts Research Institute The University of
Western Ontario, London,, ON, Canada, 3Abbott Laboratories, Abbott Park, IL, USA, 4Abbott
Laboratories, Saint-Laurent, QC, Canada
OBJECTIVES: TNF antagonists are effective therapy for moderate to severe active
Crohn’s disease (CD). Despite their efficacy, these monoclonal antibodies are asso-
ciated with high treatment costs. The objective was to evaluate the economic
impact of the introduction of anti-TNFs for CD treatment on health care resource
utilization fromahealth care systemperspective.METHODS:A retrospective study
was conducted using a random sample of patients diagnosed with CD (ICD-
9555.x) who initiated adalimumab or infliximab therapy between January 2001
and December 2009. Prescription and medical data from the Régie de l’assurance-
maladie du Québec were also obtained from three samples of age- and gender-
matched controls: 1) general population; 2) CD patients treated neither with anti-
TNFs nor antimetabolites; and 3) CD patients taking only antimetabolites. Health
care resource utilization and costs were estimated for the year preceding and fol-
lowing index date. Disease severity was assessed through prednisone and antime-
tabolite use and healthcare resource utilization in the year before index date.
RESULTS: A cohort of 614 patients was obtained (mean age40.5years, 61% fe-
males). Anti-TNF treated patients’ average cost for health care resources was
CAN$7,202. In comparison, costs in the general population, patients treated neither
with anti-TNFs nor antimetabolites, and patients taking only antimetabolites,were
CAN$1,093, CAN$2,029, and CAN$3,024 respectively. In the year before anti-TNF
initiation, CD patients received more prednisone and antimetabolites and used
more health care resources. Following anti-TNF initiation, the cost of drugs re-
ceived was higher for this cohort, but costs of medical visits, ER visits and hospi-
talizations were significantly lower (CAN$882 vs. CAN$554, CAN$297 vs. CAN$161,
and CAN$5,423 vs. CAN$2,963, respectively, p0.001 for all). CONCLUSIONS: Bio-
logic users are more likely to have severe CD than controls resulting in higher
medical resource consumption and greater prednisone and antimetabolites use.
Initiation of a biologic treatment in these patients is associated with lower health
care resource utilization and cost offsets.
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OBJECTIVES: Several studies show that adherence is an important factor to treat-
ment success, improving patient outcomes and reducing global costs. The aim of
this study is to estimate the clinical and economic impact of non-adherence by
patients with ulcerative colitis in remission that are undermaintenance treatment
with mesalazine in the Brazilian Public Healthcare perspective. METHODS: We
compared two schemes of Mesalazine 2 grams/per day: once daily (2 grams sachet)
or twice daily (two 500 mg capsules q12). We constructed a decision tree analytical
model to compare costs and outcomes of Mesalazine once daily (MOD) with Me-
salazine twice daily (MTD) over 12 months. Treatment pathways described in the
model are based on Brazilian Government Clinic and Therapeutics Guidelines,
therefore, biological drugs were not considered in this analysis, because there are
not reimbursed. In both arms, the failure to maintain remission led to other treat-
ments, as needed: prednisone, cyclosporin, azatioprine and colectomy. Adherence
data was obtained from real life prospective studies (Kane et. al.). Costs considered
were: drug, laboratory and diagnostic tests’ costs, specialist consultation and hos-
pitalization costs (all costs are referred to year 2011). The mains outcomes consid-
ered were colectomy surgery avoided and rates of remission without relapse.
RESULTS: Results of the analysis suggest that the average aggregated treatment
cost per person for all medical interventions at 12 months was lower for MOD
compared with MTD (USD 1924 versus USD 1957). Additionally, there is a trend
towards improved effectiveness with MOD inmaintenance remission of ulcerative
colitis with 6.6% re-inductions and 17.2% colectomy surgeries avoided.
CONCLUSIONS: Results from base-case and sensitivity analysis indicate that MOD
presents lower costs and better effectiveness than MTD from a public payers’ per-
spective in Brazil.
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OBJECTIVES: To compare the all-causemedical resource utilization in chronic liver
disease (CLD) patients with thrombocytopenia (TCP) versus no thrombocytopenia,
using the Veterans health administration (VHA) database. METHODS: All utiliza-
tion records of patients in the VA national patient care databases, who had a
diagnosis of CLD between 1999 and 2008, were followed from the date of CLD
diagnosis to 180 days following the earlier of two events: the last date a platelet
count was available for each patient, or the date of the last platelet count of fewer
than 50,000 cells / L. Platelet counts and outcomes such as, number of physician
visits (PV) and outpatient procedures (OPP), and healthcare costs (HCC) were deter-
mined for every threemonth period up to study end for each eligible patient, using
a longitudinal per patient per 3-month dataset. Generalized linear models (GLMs)
were used to study the impact of change in platelet counts on health care utiliza-
tion and costs, after adjusting for hepatitis C infection and other covariates.
RESULTS: A total of 935 and 256,516 patient-3-month observations were available
for comparing health care use in CLD patientswith TCP versus no TCP respectively.
After adjusting for liver disease severity and other covariates incidence rate ratios
for PV and OPP for an increase in platelet counts by 25,000, were 0.992 (95% CI:
0.990-0.993, p 0.0001) and 0.989 (95% CI: 0.987 – 0.990, p 0.0001) respectively. For
a decrease in platelet counts of 10,000 and 25,000 among observations with a max-
imum platelet count of 50,000 / L during the study period, the average predicted
change in overall health care costs per quarterwas$139 (SD: $379) and$369 (SD:
$1,004), respectively (p  0.0001). CONCLUSIONS: In a VA patient population with
CLD, TCP is associated with modest increase in health care utilization and costs as
compared to no TCP.
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OBJECTIVES: Patients with chronic constipation (CC) are often treated with diverse
over the counter (OTC) laxatives, bulking agents, stool softeners, and a limited
choice of prescription (Rx) drugs. Sub-optimal treatment often results in adverse
medical events or treatmentmodifications. The purpose of this study is to estimate
healthcare resource utilization (HRU) and costs of such unmet treatment needs.
METHODS: Data from the Missouri Medicaid program covering medical services
and Rx andOTCmedications (1997-2010) were used to select adult patientswith CC
receiving constipation treatments. The index date was defined as the date of the
first constipation-treatment claim. Indicators of unmet treatment needs were ob-
served during the one-year period after the index date and defined as the following
events occurring while on constipation treatment: 1) switch to or addition of a new
constipation treatment; 2) constipation-related inpatient (IP) or emergency room
(ER) admission; 3) megacolon or fecal impaction diagnosis; 4) constipation-related
surgery/medical procedure; or 5) use of other unusual constipation treatments.
Incremental HRU and costs (USD 2010; measured from a public-payer perspective)
were compared between patients with and without indicators of unmet needs
using multivariate generalized linear regression models. RESULTS: A total of 8745
patients with CC were identified; 54.9% of them were found to have unmet needs
during the one-year period following the index date. After adjusting for baseline
differences, indicators of unmet needs were associated with more HRU, especially
the number of IP days (IRR 1.54; P0.001) and ER admissions (IRR1.35; P0.001).
Indicators of unmet needs were associated with a $2,978 incremental total annual
healthcare costs (P0.001) compared to patients without indicators of unmet
needs. The cost difference was mainly driven by IP ($2,575 vs. $1,534; P0.001) and
pharmacy ($7,114 vs. $5,929; P0.001) costs. CONCLUSIONS: Unmet treatment
needs among CC patients were associated with a significant economic burden.
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OBJECTIVES: Previous studies demonstrate that diverticulitis (DV) is costly to pay-
ers. Most research focuses on total costs and acute episodes, while the burden of
recurrent episodes is not well documented. This study assessed the direct eco-
nomic burden associated with DV recurrence among managed care enrollees.
METHODS: Data were drawn from insurance claims from 40 US health plans.
Patients with a primary DV diagnosis (ICD-9-CM 562.11 or 562.13) between January
1, 2005 to December 31, 2008 were subjected to the following criteria: antibiotic
treatment 3 days post-diagnosis and 6 months continuous pre- and 12
months post-index date (first observed DV diagnosis) plan enrollment. The first 6
weeks post-index date defined the initial acute episode period. Within a given
6-week period following the acute episode, a recurrent episode was defined by a
DV-related hospitalization or ER visit, or a DV-related office visit with antibiotic
treatment within 3 days of the visit. Those with a recurrence were stratified into
those with and without surgical intervention. Recurrence-related costs (2009 US$)
were evaluated for 12 months post-initial acute episode. RESULTS: A totall 36,636
patients were selected (53% male, mean age 52 years); 16.5% (N6,045) had 1
recurrence. Among those with 1 recurrence, the mean number (SD) of recur-
rences was 1.3 (0.6), while the total cost of all recurrences was 4 times the initial
acute episode cost ($12,806 vs. $3,132). For the surgical group (N2868), the differ-
ence between the total cost of all recurrences and initial acute episode costwas still
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